These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12658318)

  • 1. The sorry saga of the statins in New Zealand--pharmacopolitics versus patient care.
    Begg E; Sidwell A; Gardiner S; Nicholls G; Scott R
    N Z Med J; 2003 Mar; 116(1170):U360. PubMed ID: 12658318
    [No Abstract]   [Full Text] [Related]  

  • 2. Response from PHARMAC: difficult choices.
    Moodie P; Metcalfe S; McNee W
    N Z Med J; 2003 Mar; 116(1170):U361. PubMed ID: 12658319
    [No Abstract]   [Full Text] [Related]  

  • 3. Switching statins: can we do harm?
    Thomas U
    N Z Med J; 1998 Jan; 111(1058):18. PubMed ID: 9490420
    [No Abstract]   [Full Text] [Related]  

  • 4. Fluvastatin: what is the evidence?
    Bagg W; Braatvedt G
    N Z Med J; 1997 Aug; 110(1050):321-2. PubMed ID: 9315035
    [No Abstract]   [Full Text] [Related]  

  • 5. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PHARMAC and statins--getting the best population health gains.
    Moodie P; Dougherty S; Metcalfe S
    N Z Med J; 2006 Jul; 119(1238):U2092. PubMed ID: 16868585
    [No Abstract]   [Full Text] [Related]  

  • 7. PHARMAC measures savings elsewhere to the health sector.
    Metcalfe S; Dougherty S; Brougham M; Moodie P
    N Z Med J; 2003 Mar; 116(1170):U362. PubMed ID: 12658320
    [No Abstract]   [Full Text] [Related]  

  • 8. Is PHARMAC's sole-supply tendering policy harming the health of New Zealanders?
    MacKay P
    N Z Med J; 2005 May; 118(1214):U1433. PubMed ID: 15886729
    [No Abstract]   [Full Text] [Related]  

  • 9. Lowering copayments: impact of simvastatin patent expiration on patient adherence.
    Sedjo RL; Cox ER
    Am J Manag Care; 2008 Dec; 14(12):813-8. PubMed ID: 19067498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on statins.
    Mason P
    J Vasc Nurs; 2004 Jun; 22(2):49-50. PubMed ID: 15179417
    [No Abstract]   [Full Text] [Related]  

  • 11. [Coronary heart disease patient reaches LDL level of 100 mg/dl with atorvastatin: how do you continue treatment next year?].
    Weizel A; Sawicki PT
    MMW Fortschr Med; 2004 Dec; 146(51-52):14, 16. PubMed ID: 15675236
    [No Abstract]   [Full Text] [Related]  

  • 12. The change of cost: reference-based pricing and the statins.
    Thomas M
    Can J Cardiol; 1999 May; 15(5):535-8. PubMed ID: 10350662
    [No Abstract]   [Full Text] [Related]  

  • 13. Toward a role for statins in immunomodulation.
    Mach F
    Mol Interv; 2002 Dec; 2(8):478-80. PubMed ID: 14993398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluvastatin cost considerations.
    Garnett WR
    Ann Pharmacother; 1994 Sep; 28(9):1111-2. PubMed ID: 7803895
    [No Abstract]   [Full Text] [Related]  

  • 15. Differences between statins on clinical endpoints: a population-based cohort study.
    Dieleman JP; van Wyk JT; van Wijk MA; van Herpen G; Straus SM; Dunselman H; Sturkenboom MC
    Curr Med Res Opin; 2005 Sep; 21(9):1461-8. PubMed ID: 16197665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PHARMAC and the statin debacle.
    Ellis C; White H
    N Z Med J; 2006 Jun; 119(1236):U2033. PubMed ID: 16807576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statins and osteoporosis: new role for old drugs.
    Jadhav SB; Jain GK
    J Pharm Pharmacol; 2006 Jan; 58(1):3-18. PubMed ID: 16393459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Which statin is more efficient? Concepts and applications in economic evaluation].
    García-Altés A; Jovell AJ
    Aten Primaria; 2000 Sep; 26(5):333-8. PubMed ID: 11100606
    [No Abstract]   [Full Text] [Related]  

  • 19. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
    Hirsch M; O'Donnell JC; Jones P
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):18-28. PubMed ID: 15703502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular health in New Zealand: areas of concern and targets for improvement in 2008 and beyond.
    Ellis CJ; Hamer AW
    N Z Med J; 2008 Feb; 121(1269):5-10. PubMed ID: 18278077
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.